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Growth Hormone (GH) Secretion in Patients with Childhood-Onset GH Deficiency: Retesting after One Year of Therapy and at Final Height
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Abstract
Background: Recent studies have shown that many patients treated with growth hormone (GH) during childhood because of idiopathic GH deficiency (GHD) are no longer GH deficient when retested after cessation of GH therapy when final height is achieved. These patients are labelled as transient GHD. We hypothesized that normalization of GH secretion in transient GHD could occur earlier during the course of GH treatment, which could allow earlier cessation of GH treatment. 
Methods: In a retrospective study, GH secretion was re-evaluated after cessation of GH treatment at final height in 43 patients diagnosed during childhood as idiopathic GHD (10 with multiple pituitary hormonal deficiencies (MPHD) and 33 with isolated GHD (IsGHD)). In a prospective study, GH secretion was re-assessed after interruption of GH treatment given for 1 year in 18 children with idiopathic GHD (2 MPHD, 16 IsGHD). GH secretion was evaluated by glucagon or insulin stimulation tests. 
Results: In the retrospective study, all the 10 patients with MPHD and 64% of the 33 patients with IsGHD were still deficient at re-evaluation using the paediatric criteria to define GHD (GH peak <10 ng/ml at provocative test). The proportion of persisting deficiency was greater in patients with complete IsGHD (86%, 12/14 patients) than in patients with partial IsGHD (47%, 9/19 patients). With the criteria proposed in adulthood (GH peak <3 ng/ml), all the 10 patients with MPHD were still considered to be deficient. In contrast, only 15% (5/33 patients) with IsGHD had a maximal GH value <3 ng/ml (36% of the 14 patients with complete IsGHD and none of the 19 patients with partial IsGHD). In the prospective study, after interruption of GH therapy given for 1 year, the 2 patients with MPHD were still GHD at re-evaluation and they resumed GH treatment. Among the 16 patients with IsGHD, 13 (81%) were still deficient (peak response <10 ng/ml) after 1 year. Two of the 3 patients in whom GHD was not confirmed at retesting after 1 year GH showed again a deficient response at second retesting. 
Conclusions: Although many patients diagnosed with IsGHD during childhood have a normalized GH secretory capacity when retested during adulthood, early retesting after interruption of GH treatment given for 1 year during childhood does not enable to determine if GH therapy has to be discontinued before cessation of growth.
Key Words: Idiopathic growth hormone deficiency ; Growth hormone treatment ; Retesting

Introduction
Present growth hormone (GH) treatment regimens of children with idiopathic GH deficiency (GHD) result in a normalization of growth and final height in most of them [1-3]. However, it has been established that a considerable number of patients (up to 80%), diagnosed as having idiopathic GHD in childhood or during adolescence, have a normalized GH secretion when re-evaluated at attainment of final height when GH treatment is stopped (so-called transient GHD) [4-12]. The question arises whether these patients really need GH treatment until attainment of final height. Transient GHD might resolve before attainment of adult height. Then, a short period of GH therapy could be sufficient to treat transient GHD and GH treatment could possibly be interrupted before attainment of final height, resulting in a relief for the patients and parents and also in important economical benefits.

In a retrospective study, we re-assessed GH secretion in young adult patients with childhood-onset idiopathic GHD treated with GH until attainment of final height. The objective was to determine which proportion had a normalized GH secretion after the end of therapy using paediatric (maximal GH value < 10 ng/ml at provocative test) as well as adult (maximal GH value <3 ng/ml) criteria. In a prospective study, we re-evaluated GH secretion in children with idiopathic GHD after interruption of GH therapy given for 1 year and assessed whether this early retesting could show normalization of GH secretion in the patients with transient GHD before the end of growth.
Methods
Subjects
Forty-three patients (23 boys) diagnosed during childhood as having idiopathic GHD and having reached final height between 1993 and 1995 participated in the retrospective study on reassessment of GH secretion after the end of therapy. Eighteen patients (12 boys), diagnosed as idiopathic GHD between 1994 and 1998, were included in the prospective study on early reassessment of GH secretion. Table 1 shows the patient characteristics. All patients were followed in the departments of paediatric endocrinology of the seven Belgian universities. The studies were approved by the local ethical committees and informed consent was obtained from all patients and parents.

Table 1. Characteristics (mean ± SD or numbers) of the studied patient groups at the onset of GH therapy
	Retrospective (n = 43)	Prospective (n=18)
Age at initial testing, years	9.6 ± 3.7	10.7 ± 3.0





Height (SDS)	-2.8 ± 0.7	-2.7 ± 1.1
Mid-parental height (SDS)	-0.4 ± 0.9	-0.6 ± 0.8
Height velocity, cm/year	4.2 ± 1.1	4.0 ± 1.0

Methods
Initial diagnosis of GHD was established on the basis of auxological (height velocity below the 25th percentile) and biological criteria (peak GH values after two GH stimulation tests (glucagon, insulin) <10 ng/ml) and peer-reviewed by the members of the BSGPE at monthly meetings. In the retrospective study, prepubertal patients with a bone age > 10 years were sex steroid primed before GH testing: in boys, 50 mg of propionate of testosterone was administered intramuscularly 72 h before the GH stimulation test, and the girls received 50 µg ethinyloestradiol orally daily for 3 days before the test. In the prospective study, a sex steroid priming was made for boys aged 10 years or older and for girls aged 9 years or more, independently of bone age. Such a priming was performed both at diagnosis and at retesting after 1 year of treatment. GHD was considered as complete when the maximal GH values at the two tests were < 5 ng/ ml; GHD was considered as partial when the maximal GH values at the two tests were < 10 ng/ml with at least one > 5 ng/ml.
In the retrospective study, late retesting was performed between 0.2 and 40 months (median: 4 months) after the cessation of GH therapy with a glucagon stimulation test (n = 36) or an insulin tolerance test (ITT) (n = 7). The proportion of patients with a GH peak < 10 ng/ml (definition of childhood GHD) and <3 ng/ml (definition of adult GHD) was calculated. In the prospective study, retesting was done with a glucagon stimulation test after 1 year of GH therapy and after a treatment interruption period of 2-6 weeks. In the patients with early retesting confirming GHD, GH treatment was resumed after 3 months of interruption, except when indicated otherwise. Two patients underwent a second retesting according to the same protocol 2 years after the first retesting. The proportion of patients with a GH peak < 10 ng/ml was calculated and the growth of the patients was followed. Comparison between initial testing and retesting was based on the glucagon test in the prospective study. The GH assays were performed using commercially available GH-RIA/IRMA kits in the laboratories of the different university hospitals. The inter-laboratory coefficient of variation was 13.0% at the level of 6.6 ng/ ml, and 12.4% at the level of 13.0 ng/ml. For a same subject, the GH concentrations were determined in the same laboratory using the same method. If other pituitary deficiencies were present the patients were considered as multiple pituitary hormone deficient (MPHD) and they received adequate substitution therapy. The other patients are labelled as isolated GHD (IsGHD).
GHD was defined as idiopathic GHD in the absence of any evidence for a CNS tumour or a pituitary or hypothalamic malformation on cranial CT scanning. In the retrospective study, 19 patients, and in the prospective study, 16 patients were evaluated by MR imaging. Patients with pituitary hypoplasia (retrospective study n = 2 (1 MPHD, 1 IsGHD); prospective study n = 5 (all IsGHD)), pituitary stalk interruption syndrome (retrospective study n = 7 (6 MPHD, 1 IsGHD); prospective study = 2 (both MPHD)) or ectopic posterior pituitary gland (retrospective study n = 1 (IsGHD)) were considered as idiopathic GHD. The other patients had a normal MRI (retrospective study n = 9 (1 MPHD, 8 IsGHD) prospective study n = 9 (9 IsGHD)).
All patients were treated with recombinant human GH in a dose of 0.5-0.7 IU/kg/week (0.17-0.23 mg/kg/week). The patients were seen every 3 months in the outpatient clinic. Height was measured with a Harpenden stadiometer. Height data were expressed as standard deviation scores (SDS) using the Tanner references [13]. Pubertal development was evaluated according to Tanner [14] and the testicular volume was measured with a Prader orchidometer. Onset of puberty was defined by a testicular volume ≥ 4 ml in boys and by the presence of breast stage 2 (B2) in girls. Mid-parental height SDS was calculated as: (height SDSfather + height SDSmother)/2. Target range (cm) was calculated as [(father's height + mother's height ± 13 cm)/ 2] ± 8.5 cm [15].
Results are expressed as mean ± SD or as individual values as indicated. Within group comparisons were done with the paired t-test and between group comparisons with the Mann-Whitney U-test. A p value <0.05 was considered as significant.






Ten patients had MPHD (7 patients had GH, TSH, gonadotropin and ACTH deficiency, 2 had GH, TSH and ACTH deficiency, and 1 had GH and TSH deficiency) and all of them had complete GHD at initial evaluation. All the 10 patients with MPHD (100%) were still GHD at re-evaluation using paediatric as well as adult criteria (fig. 1a, table 2).
Among the patients with IsGHD (n = 33), 14 had complete and 19 had partial GHD at initial evaluation. Using the paediatric cut-off level, persisting GHD at retesting was seen in 12 (86%) of the patients with complete GHD and only 9 (47%) of those with partial GHD. Using the adult cut-off level, only 5 (36%) of the patients diagnosed as complete GHD and none (0%) of the patients with partial GHD were still deficient at retesting (fig. lb, table 2).
In the 7 patients with pituitary stalk interruption and in the 2 patients with pituitary hypoplasia on MRI, the diagnosis of GHD was confirmed using paediatric and adult criteria (1 patient with pituitary stalk interruption syndrome and IsGHD had a value just >3 ng/ml at retesting (3.4 ng/ml)). In the patient with documented ectopic posterior pituitary gland, the diagnosis was confirmed using paediatric criteria but not according to the adult criteria (maximal GH value at retesting of 7.4 ng/ml).
Table 3 shows the auxological parameters in the patients with MPHD, and the patients with persisting or non-persisting IsGHD in adulthood. The auxological parameters are compared between the patients with persisting and non-persisting IsGHD (using adult criteria). Patients with persisting GHD were smaller at the start of GH treatment. The short- and long-term growth response was comparable in the two groups. All but 2 patients (with non-persisting IsGHD) reached a final height within their target range.
Prospective Study
Two patients had MPHD (1 had complete GH, TSH, gonadotropin and ACTH deficiency, 1 had partial GH, TSH and ADH deficiency). Both of them were still GHD (peak response <10 ng/ml) at re-evaluation after 1 year GH therapy and they resumed GH treatment (fig. 2). These 2 patients showed hypothalamic-pituitary abnormalities at MRI.
Among the 16 patients with IsGHD, 4 had complete and 12 had partial GHD at initial evaluation. At re-evaluation after interruption of GH therapy given for 1 year, all (100%) of the patients with complete GHD and 9 (75%) of those with partial GHD showed evidence of persisting deficiency (peak response <10 ng/ml). One patient with complete IsGHD became partial GHD. Three patients (25%) showed a normalized response of GH at retesting (fig. 2).
Follow-Up of the Patients Re-Evaluated after 1 Year of GH Therapy (table 4)
The individual patients are identified by the numbers in parentheses (patients (pts) x) which refer to the same numbers in figures 2 and 3, and table 4. The 2 patients with MPHD (pts 1,2) resumed GH therapy after re-evaluation and had a good growth response (respectively 12.1 and 10.7 cm during the first year; 10.3 and 8.3 cm during the second year). Not illustrated in figure 3a.
Of the 16 patients with IsGHD retested after 1 year of GH treatment, only 8 (pts 3-10) resumed GH therapy after 3 months of interruption. All of them had evidence of persisting GHD at retesting. These patients doubled their height velocity during the first year of treatment (fig. 3a; before: 4.1 ± 0.9 cm/year; during year 1: 9.2 ± 2.2 cm/year; p < 0.001). During the second year of GH treatment, height velocity declined but remained above pretreatment levels (7.3 ± 1.5 cm/year; p < 0.001). Four of these patients were retested after completion of GH treatment: 1 was still complete GHD (0.5 ng/ml) (pt 4), 1 confirmed his partial GHD (6.8 ng/ml) (pt 8), while the 2 others had a normalized GH response (peak: 10.1 ng/ml (pt 9), peak: 42.3 ng/ml (pt 10)).
Eight patients (pts 11-18) did not resume GH therapy after 3 months of interruption: 5 of them had GHD confirmed, whereas the 3 others showed a normalized GH response at retesting. Their growth pattern is shown in figure 3b. Two patients (pts 11, 12), with persisting GHD at retesting, did not want to resume treatment and their height velocity fell to 2.5 and 4.1 cm/year. In 2 patients (pts 13, 14) GH therapy was stopped because their height velocity increment during GH treatment was <2 cm/year above the pretreatment level. One of these patients (pt 13) entered into puberty and showed an acceleration in height velocity to 8.1 cm/year without GH therapy. One patient (pt 15) did not resume therapy because height velocity appeared sufficient without treatment (6.5 cm/year). This patient was re-evaluated at adult height and showed a normalized GH response of 11.9 ng/ml.
The 3 patients (pts 16-18) in whom GHD was not confirmed at retesting did initially not resume GH treatment. Their height velocity decreased during the period off GH to respectively 4.0, 3.2 and 4.5 cm/year. Patients 16 and 17 were retested again 2 years after the first retesting and these patients turned out to be again GHD (peak GH responses of 9.3 and 5.6 ng/ml, respectively) (fig. 2). GH treatment was resumed and resulted in significant growth response (fig. 3b). Patient 18 who did not resume GH therapy reached a final height of 154.2 cm, which was within target range (156.5 ± 8.5 cm).






Table 2. Frequency of confirmation of GHD during the re-evaluation after GH therapy in function of the aetiology, the severity of GHD and the cut-off level to define GHD in the patients of the retrospective study
Type of pituitary deficiency	Patients	Patients with confirmed GHD, %
		GH peak <10ng/ml	GH peak <3ng/ml
MPHD	Complete GHD	         10	10 (100%)	10 (100%)
	Complete GHD			14		12 (86%)		5 (36%)
IsGHD    		33			21 (64%)		5(15%)	
	Partial GHD			19		9 (47%)		0 (0%)









Table 3. Auxological variables of the patients with persisting MPHD, with persisting IsGHD and with non-persisting IsGHD in adulthood and comparison of the auxological variables between the two last groups
Auxological variables	Patients with persisting MPHD (n=10)	Patients with persisting IsGHD (n=5)	Patients with non-persisting IsGHD (n = 28)
Chronological age at onset of GH therapy, years	8.3 ± 3.3	8.9 ± 5.5	11.3 ± 2.7
Height at onset of GH therapy (SDS)	-2.9 ± 0.9	-3.6 ± 0.6	-2.6 ± 0.6*
Height at onset of puberty (SDS)	-1.1 ± 0.8	-1.8 ± 1.1	-1.9 ± 0.8
Final height (SDS)	0.1 ± 0.9	-1.3 ± 0.6	-0.6 ± 0.9
Target height (SDS)	0.0 ± 1.1	-1.0 ± 1.1	-0.5 ± 0.8
Final height corrected for target height (SDS)	0.2 ± 0.9	-0.2 ± 0.6	-0.1 ± 0.8
Delta height SDS during first year of GH therapy	0.7 ± 0.3	0.7 ± 0.3	0.6 ± 0.4
Delta height SDS during second year of GH therapy	0.5 ± 0.3	0.7 ±0.2	0.5 ± 0.4
Total height gain (SDS)	3.0 ± 1.1	2.3 ± 1.1	2.0 ± 0.8
*p<0.01: patients with persisting IsGHD versus patients with non-persisting IsGHD.

Table 4. Results of GH retesting and follow-up of patients in the prospective study
Patient   	 Gender	Type of deficiency	Complete (C) or partial (P) GHD	GH peak atretestingng/ml	Additional GH testing	Follow-up
1	M	MPHD	C	0.5	ND	GH treatment resumed, good growth response, still growing
2	M	MPHD	P	4.7	ND	GH treatment resumed, good growth response, still growing
3	F	IGHD	C	0.4	ND	GH treatment resumed, good growth response, FH: 140.9 cm (TH: 153.0 ± 8.5 cm)
4	F	IGHD	C	0.5	At FH: 0.5	GH treatment resumed, good growth response, FH: 151.5 cm (TH: 149.0 ± 8.5 cm)
5	F	IGHD	C	0.7	ND	GH treatment resumed, good growth response, still growing
6	M	IGHD	P	4.6	ND	GH treatment resumed, good growth response, still growing
7	M	IGHD	P	5.6	ND	GH treatment resumed, good growth response, still growing
8	M	IGHD	P	7.2	At FH: 6.8	GH treatment resumed, good growth response, FH: 169.6 cm (TH: 172.5 ± 8.5 cm)
9	M	IGHD	P	9.5	At FH: 10.1	GH treatment resumed, good growth response, FH: 154.5 cm (TH: 170 ± 8.5 cm)
10	F	IGHD	P	9.6	At FH: 42.3	GH treatment resumed, good growth response, FH: 146.1 cm (TH: 153.5 ± 8.5 cm)
11	M	IGHD	P	5.7	ND	GH stopped, patient's decision
12	M	IGHD	P	8.8	ND	GH stopped, patient's decision, FH: 169.5 cm (TH: 172.0 ± 8.5 cm)
13	M	IGHD	P	5.8	ND	GH stopped because of slow HV (5.1 cm/year) during first year GH treatment, FH: 161.5 cm (TH: 171.0 ± 8.5 cm)
14	M	IGHD	P	8.2	ND	GH stopped because of slow HV (5.3 cm/year) during first year GH treatment, still growing
15	M	IGHD	C	5.7	At FH: 11.9	GH stopped because of sufficient HV (6.5 cm/year) without GH, final height: 171.5 cm (TH: 178.3 ± 8.5 cm)
16	M	IGHD	P	11.1	9.3	GH stopped because of normal retesting, slow HV without GH, treatment resumed after new retesting
17	F	IGHD	P	16.0	5.6	GH stopped because of normal retesting, slow HV without GH, treatment resumed after new retesting
18	F	IGHD	P	20.0	ND	GH stopped because of normal retesting, FH: 154.2 cm (TH: 156.5 ± 8.5 cm)
ND = Not done, FH = final height, TH = target height.
Discussion
Our retrospective study revealed that a significant number of patients (64%) diagnosed as having idiopathic IsGHD in childhood are not GHD anymore after the end of GH therapy at attainment of final height. In contrast, in our prospective study, most of the early retested patients with IsGHD (81%) were still GHD 1 year after the onset of GH treatment.
The results we obtained in our retrospective study are consistent with the data of the literature [4-12] although the proportion of persisting GHD varies from one study to another. In the patients with MPHD, persisting GHD was confirmed in the majority of the patients [4, 9, 11]. In the patients with IsGHD, the results are more heterogeneous. Using paediatric criteria, only 12% of the patients are still GHD at adult height in the study of Wacharasindhu et al. [8], while this proportion goes up to 33% and even 74% in the series of Tauber et al. [10] and Clayton et al. [4].
The severity of the initial deficiency influences the proportion of patients for which the GHD is confirmed. In our study, using paediatric criteria, the patients with complete IsGHD had a higher proportion of persisting GHD at the final evaluation (86%) than those with partial IsGHD (47%). Similar findings were reported by Tauber et al. [10]: they found 64% persisting deficiency at the final evaluation in patients with complete IsGHD while it was only 29% in those with partial IsGHD (a majority of patients with idiopathic GHD).
Another important factor that influences the proportion of patients who normalize their GH secretion is the criterion used to define adult GHD. In a child with clinical criteria for GHD, a peak GH concentration < 10 ng/ml is used to support the diagnosis [16] whereas in adults, a peak GH response <3 ng/ml is used [17]. In our study, 15 % of the patients with IsGHD had persisting deficiency after therapy using adult criteria and could deserve continuation of GH treatment in adult life. None of the patients with initial partial IsGHD fulfilled the criteria for persisting deficiency in adulthood. In two other studies, the proportion of persisting GHD using adult criteria varied between 14% [10] and 53% [7] of the patients with idiopathic GHD.
Another factor that could influence the proportion of patients who normalize their GH secretion is the presence of sex steroids. It is well documented that deficiency of sex steroids during the pubertal age range can result in an insufficient increase of GH during stimulation tests [18-20]. Sex steroid priming, as performed in the present study, has been advocated to reduce the number of false-positive diagnoses of GHD [18-20]. It remains, however, unclear whether the (unphysiological) way of priming with sex steroids is sufficient to overcome in all cases the influence of lack of sex steroids on GH secretion. In fact, we believe that a large number of the cases with 'transient' GHD are due to inappropriate low levels of sex steroids.
Moreover, we may not forget that there exists a continuum of GH secretion that ranges from normal GH secretion to severe GHD, as seen in congenital or acquired MPHD, and that overlap exists in peak GH concentrations between normal children and those with GHD. The cut-off level of 10 ng/ml therefore remains rather arbitrary, especially if the wide diversity in GH measurements due to assay variability is taken into account [21-24]. In our study, the inter-laboratory coefficient of variation was about 13%, and for the sake of simplicity only one fixed cut-off level was used. We do not believe that assay specific cut-off levels would yield in different conclusions in the present study.
Looking for auxological criteria predictive for permanent GHD, we found that patients with persisting GHD were smaller at the start of GH treatment than the patients with non-persisting GHD. This might reflect a more profound degree of GHD: all patients with persisting GHD had initially complete GHD. However, the short- and long-term growth response to GH therapy in terms of height gain and final height were comparable in the two groups. This finding is agreement with the data of Tauber et al. [10] who also found no relationship between catch-up growth and GH response after cessation of treatment: in patients with complete as well as in those with partial GHD, they did not find any difference in total height gain between those who normalized their test and those who did not.
Another predictive criterion for permanent GHD in adults seems to be the MRI finding of a congenital hypo-thalamic-pituitary abnormality. Maghnie et al. [11] reevaluated GHD patients subdivided according to the pituitary MRI. All patients with IsGHD and normal or small pituitary volume showed normalization of GH secretion whereas GHD was permanent (<3 ng/ml) in patients with pituitary hypoplasia, pituitary stalk agenesis and ectopic posterior pituitary gland. Although MRI data were incomplete in our retrospective study, the 7 patients in our series with documented pituitary stalk interruption and the 2 patients with pituitary hypoplasia had persisting GHD according to the adult criterion, whereas in the patient with posterior pituitary ectopia without stalk interruption, the deficiency was confirmed using paediatric criteria but not confirmed according to the adult criteria.
So, except for the patients with MPHD, it seems impossible to predict persistence of GHD on the basis of auxological or biochemical criteria, particularly in patients with idiopathic GHD and without congenital hypo-thalamic-pituitary abnormality like pituitary stalk interruption. Retesting young adults with childhood-onset idiopathic IsGHD is thus strongly advocated [25].
If we accept that transient GHD exists, the moment when the GH secretion could normalize is so far not known. In our prospective study, we hypothesized that in patients with transient GHD, normalization of GH secretion could occur before the end of growth, enabling an earlier cessation of GH treatment without unfavourable effect on final height. The results of the prospective study, however, showed that the vast majority of the patients had persisting GHD (peak GH < 10 ng/ml) when retested after interruption of GH therapy given for 1 year. The 2 patients with MPHD were still deficient after 1 year. For these patients, retesting after 1 year GH therapy does not seem to provide any additional information. In the patients with IsGHD, 81% (13/16) were still deficient at reevaluation after interruption of GH therapy given for 1 year. Furthermore, 2 out of the 3 patients who showed a normalization of GH secretion during the first retesting were again GHD when retested 2 years later. A 'normal' GH value at retesting probably does not signify a normalization of GH secretion but reflects the high within-subject variability of GH secretion over time. Comparable results were reported by Cacciari et al. [26] who retested 184 children with GHD diagnosed by a pathologic pharmacological or physiological (sleep) test. At first retesting, about 2.8 ± 1.1 years after the start of GH therapy, 81.5% of the patients had persisting GHD whereas 18.5% of them had normalized GH secretion at both pharmacological and physiological tests. Sixty-eight patients underwent a second retesting and none of the patients who had normalized GH secretion at first retesting, maintained normal GH secretion at second retesting. Normalization of GH secretion at early retesting may not necessarily represent the end of a transient secretory defect.
In agreement with Cacciari et al. [26] who concluded that early retesting does not represent a reliable tool for predicting the response to GH treatment, we could not find any meaningful relationship between the results of early retesting and growth. Some patients who still showed evidence of GHD might grow satisfactorily without therapy and the few who showed normalized response may still need GH therapy to obtain a satisfactory growth rate. Early retesting of patients with IsGHD does not reliably enable to predict non-persisting GHD and to identify patients who could prematurely stop GH treatment. Obviously, because we do not have in hand the data on GH response at final height in our prospective study, we can only claim that a majority of patients with IsGHD will have normalized peak responses at that time, which is quite likely.
Our studies highlight the difficulty to make a diagnosis of IsGHD. In short, slowly growing children fulfilling the clinical criteria for GHD, the diagnosis of GHD is conventionally achieved by two separate provocative tests, this being considered as the gold standard [16]. The proper interpretation of these tests is not trivial due to the low reproducibility of the stimulation tests [27], the variability of GH levels according to the assay [21-24], the potential role of puberty and sex steroids [ 18-20], the confusion with constitutional delay of growth and puberty and the influence of factors such as nutritional status, and psychosocial conditions [16].
In conclusion, our studies demonstrate that a majority of children diagnosed as idiopathic IsGHD do not have a persisting deficiency into adulthood. Having persisting or non-persisting GHD seems to have no impact on the effectiveness of GH treatment in childhood and adolescence. It remains, however, important to re-evaluate patients with childhood-onset and idiopathic IsGHD before continuing GH treatment during adult life. A more detailed assessment of persisting GHD could be performed using tools such as IGF-1, IGF-BP3 [9] and the cerebral MRI [11]. Early retesting after interruption of GH treatment does not indicate whether GH therapy has to be continued or not during childhood, and is of limited value even in patients with partial IsGHD.
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